FY2025 EPS Estimate for DarioHealth Reduced by Analyst

DarioHealth Corp. (NASDAQ:DRIO) – Analysts at Litchfield Hills Research reduced their FY2025 EPS estimates for shares of DarioHealth in a research report issued to clients and investors on Thursday, January 22nd. Litchfield Hills Research analyst T. O’neill now forecasts that the company will post earnings of ($12.36) per share for the year, down from their previous forecast of ($12.34). The consensus estimate for DarioHealth’s current full-year earnings is ($1.18) per share. Litchfield Hills Research also issued estimates for DarioHealth’s Q4 2025 earnings at ($1.80) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($4.00) EPS.

Other analysts have also issued reports about the stock. TD Cowen reiterated a “hold” rating on shares of DarioHealth in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DarioHealth in a research note on Monday, December 29th. Stifel Nicolaus set a $16.00 target price on DarioHealth in a report on Friday, November 14th. Finally, Wall Street Zen downgraded DarioHealth from a “hold” rating to a “sell” rating in a research report on Sunday. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, DarioHealth currently has a consensus rating of “Hold” and a consensus target price of $32.00.

DarioHealth Stock Performance

NASDAQ:DRIO opened at $11.64 on Monday. The company has a current ratio of 4.55, a quick ratio of 4.02 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $78.69 million, a P/E ratio of -1.04 and a beta of 1.05. The firm has a 50-day moving average price of $11.99 and a two-hundred day moving average price of $11.98. DarioHealth has a twelve month low of $5.93 and a twelve month high of $17.74.

Institutional Trading of DarioHealth

A hedge fund recently raised its stake in DarioHealth stock. XTX Topco Ltd raised its holdings in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 62,511 shares of the company’s stock after acquiring an additional 43,513 shares during the period. XTX Topco Ltd owned 0.14% of DarioHealth worth $42,000 at the end of the most recent reporting period. Institutional investors own 33.39% of the company’s stock.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.